Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.

Yoshiya Tanaka,Tsutomu Takeuchi,Derek Haaland,Stephen Hall,Nevsun Inanc,Zhanguo Li,Ricardo M Xavier, Carlos Cara,Nicola Tilt,Peter C Taylor

International journal of rheumatic diseases（2023）

引用 0|浏览18

暂无评分

摘要

CZP showed steady efficacy across baseline RF quartiles in patients with early and established RA, over 24 weeks. CZP treatment may be considered in patients with RA irrespective of baseline RF levels and time from diagnosis.

查看译文

关键词

certolizumab pegol, rheumatoid arthritis, rheumatoid factor, tumor necrosis factor inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要